ミトコンドリアミオパチー治療の世界市場（2022年～2029年）

当レポートでは、世界のミトコンドリアミオパチー治療市場を調査しており、市場の概要、市場規模や予測、動向、成長要因および課題、顧客情勢、タイプ・検査タイプ・薬剤タイプ・治療タイプ・流通チャネル・地域別の分析、さら企業プロファイルなどを提供しています。

目次

第1章 調査手法と範囲

• 調査手法
• 調査の目的と調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

• タイプ別の市場内訳
• 検査タイプ別の市場内訳
• 薬剤タイプ別の市場内訳
• 治療タイプ別の市場内訳
• 流通チャネル別の市場内訳
• 地域別の市場内訳

第4章 市場力学

• 市場に影響を与える要因
  • 促進要因
  • 抑制要因
  • 市場機会
  • 影響分析

第5章 業界分析

• サプライチェーン分析
• 価格分析
• アンメットニーズ

第6章 COVID-19分析

• 市場へのCOVID-19の影響分析
  • COVID-19前の市場シナリオ
  • 現在のCOVID-19市場シナリオ
  • COVID-19後または将来のシナリオ
• COVID-19における価格変動
• 需要と供給のスペクトル
• パンデミック時の市場に関連する政府のイニシアチブ
• メーカーの戦略的イニシアチブ
• 結論

第7章 タイプ別

• イントロダクション
  • タイプ別の市場規模分析、および前年比成長分析
  • タイプ別の市場魅力指数
• カーンズ・セイヤー症候群
  • イントロダクション
  • 市場規模分析（2020年～2029年、および2021年～2029年）
• ミトコンドリアDNA枯渇症候群（MDS）
• ミトコンドリア脳筋症、乳酸アシドーシス、および脳卒中様エピソード（MELAS）
• 母性遺伝の難聴と糖尿病（MIDD）
• ミトコンドリア神経胃腸脳筋症（MNGIE）
• ぼろぼろの赤繊維を伴うミオクローヌスてんかん症（MERRF）
• ニューロパシー、運動失調、および色素性網膜炎（NARP）
• ピアソン症候群
• その他

第8章 検査タイプ別

• イントロダクション
  • 検査タイプ別の市場規模分析、および前年比成長分析
  • 検査タイプ別の市場魅力指数
• 遺伝子検査
  • イントロダクション
  • 市場規模分析（2020年～2029年、および2021年～2029年）
• 筋生検
• 血液酵素検査
• その他の検査

第9章 薬剤タイプ別

• イントロダクション
  • 薬剤タイプ別の市場規模分析、および前年比成長分析
  • 薬剤タイプ別の市場魅力指数
• CoQ10
  • イントロダクション
  • 市場規模分析（2020年～2029年、および2021年～2029年）
• L-カルニチン
• クレアチン
• その他

第10章 治療タイプ別

• イントロダクション
  • 治療タイプ別の市場規模分析、および前年比成長分析
  • 治療タイプ別の市場魅力指数
• ビタミン
  • イントロダクション
  • 市場規模分析（2020年～2029年、および2021年～2029年）
• 酸化防止剤
• 支持療法と標的療法
• その他

第11章 流通チャネル別

• イントロダクション
  • 流通チャネル別の市場規模分析、および前年比成長分析
  • 流通チャネル別の市場魅力指数
• 病院薬局
  • イントロダクション
  • 市場規模分析（2020年～2029年、および2021年～2029年）
• 小売薬局
• オンライン薬局
• その他

第12章 地域別

• イントロダクション
  • 地域別の市場規模分析（2020年～2029年、および2021年～2029年）
  • 地域別の市場魅力指数
• 北米
  • イントロダクション
  • 主要な地域固有のダイナミクス
  • タイプ別の市場規模分析、および前年比成長分析
  • 検査タイプ別の市場規模分析、および前年比成長分析
  • 薬剤タイプ別の市場規模分析、および前年比成長分析
  • 治療タイプ別の市場規模分析、および前年比成長分析
  • 流通チャネル別の市場規模分析、および前年比成長分析
  • 国別の市場規模分析、および前年比成長分析
• 欧州
  • イントロダクション
  • 主要な地域固有のダイナミクス
  • タイプ別の市場規模分析、および前年比成長分析
  • 検査タイプ別の市場規模分析、および前年比成長分析
  • 薬剤タイプ別の市場規模分析、および前年比成長分析
  • 治療タイプ別の市場規模分析、および前年比成長分析
  • 流通チャネル別の市場規模分析、および前年比成長分析
  • 国別の市場規模分析、および前年比成長分析
• 南米
  • イントロダクション
  • 主要な地域固有のダイナミクス
  • タイプ別の市場規模分析、および前年比成長分析
  • 検査タイプ別の市場規模分析、および前年比成長分析
  • 薬剤タイプ別の市場規模分析、および前年比成長分析
  • 治療タイプ別の市場規模分析、および前年比成長分析
  • 流通チャネル別の市場規模分析、および前年比成長分析
  • 国別の市場規模分析、および前年比成長分析
• アジア太平洋
  • イントロダクション
  • 主要な地域固有のダイナミクス
  • タイプ別の市場規模分析、および前年比成長分析
  • 検査タイプ別の市場規模分析、および前年比成長分析
  • 薬剤タイプ別の市場規模分析、および前年比成長分析
  • 治療タイプ別の市場規模分析、および前年比成長分析
  • 流通チャネル別の市場規模分析、および前年比成長分析
  • 国別の市場規模分析、および前年比成長分析
• 中東とアフリカ
  • イントロダクション
  • 主要な地域固有のダイナミクス
  • タイプ別の市場規模分析、および前年比成長分析
  • 検査タイプ別の市場規模分析、および前年比成長分析
  • 薬剤タイプ別の市場規模分析、および前年比成長分析
  • 治療タイプ別の市場規模分析、および前年比成長分析
  • 流通チャネル別の市場規模分析、および前年比成長分析

第13章 競合情勢

• 主な発展と戦略
• 企業シェア分析
• 製品のベンチマーク
• 注目すべき主要企業のリスト

第14章 企業プロファイル

• Pfanstiehl, Inc.
  • 企業概要
  • 製品ポートフォリオ・種類
  • 主要ハイライト
  • 財務概要
• Ajinomoto Co., Inc.
• BOTAY BIO-CHEM CO., LIMITED
• Xi'an ZB Biotech Co., Ltd.
• Kaneka Corporation
• Lonza
• AdvaCare Pharma
• NutraBio Labs, Inc.

第15章 世界のミトコンドリアミオパチー治療市場：DataM

• 付録
• 当社・アプリケーションについて
• お問い合わせ

Market Overview

The global mitochondrial myopathies treatment market size was valued US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Mitochondrial disorders are inherited chronic conditions marked by a variety of biochemical and genetic mitochondrial abnormalities and mutations. The condition affects the brain, heart, liver, skeletal muscles, kidneys, and respiratory systems, among other organs. Patients with mitochondrial disorders frequently experience muscle weakness, exercise intolerance, and weariness as a result of a reduction in mitochondrial respiration caused by mitochondrial DNA abnormalities that result in a decreased ability to synthesize cellular adenosine triphosphate (ATP). The majority of vitamins, co-factors, off-label medications approved for other reasons, and nutritional supplements are used to treat mitochondrial problems.

Market Dynamics

Innovative therapies in the clinical trials for the treatment of Mitochondrial Myopathies are expected to drive market growth.

Mitochondrial illnesses are genetically based, neither metabolic pathways nor symptomatic treatments can fundamentally fix them. Gene therapy is therefore the best option. Most advances in mitochondrial disease gene therapy have so far been focused on LHON. Pathogenic mutations of the mtDNA encoding complex IV subunit 4 are seen in about 70% of people with LHON (MT-ND4). The adeno-associated virus (AAV) can transport mtDNA, and its capsid VP2 can fuse with a plasmid targeting sequence to reexpress ND4. The expression of wild-type ND4 in ND4 mutant cells can help to correct ATP production problems. Moreover, This is the first time gene-editing technology has been used to change mtDNA in vivo, indicating that gene-editing technologies are utilized to treat mitochondrial illnesses.

Furthermore, research has shown considerable promise and is predicted to result in more effective treatment techniques for mitochondrial illnesses. Mitochondrial biogenesis enhancers (bezafibrate, epicatechin, and RTA 408), antioxidants (RP 103 and EPI-743), and cardiolipin protectors are among the medications now being studied (elamipretide). Thus, from the above statements, the market is expected to drive in the forecast period.

Restraint:

Higher R&D costs, more stringent drug approval restrictions, and a lack of knowledge and understanding of the condition are some of the factors expected to hamper the market growth in the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. COVID-19 is extremely contagious in older people with weakened immune systems, and the risk of death rises with age and the presence of comorbidities including hypertension, diabetes, cardiovascular disease, or chronic obstructive pulmonary disease. There are several theories regarding mitochondria and their functions in inflammation that could explain why SARS-CoV-2 is wreaking havoc on the older population, particularly those with comorbidities. As a result, the importance of mitochondria in treatment development has increased. Over-stimulated or sustained inflammatory responses with interferon and cytokine production, regulation of fission and fusion, mitochondrial biogenesis, and interference with apoptosis and mitophagy are all possible linkages between aging mitochondria and reduced immunity. From bacteria to parasites to viruses like SARS-CoV-2, many pathogens have shown a predisposition to disrupt mitochondria as a strategy to influence host behavior once inside a cell by changing their processes.

Additionally, the pandemic interrupts the supply chain and clinical trials process. Many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of the economic activities.

Segment Analysis

Others segment is expected to hold the largest market share in mitochondrial myopathies treatment market

The others segment is expected to dominate in 2021. The segment is bifurcated into Mito Cocktail, Exercise, and Mitochondrial Replacement Therapy (MRT). Moreover, there is no cure for mitochondrial abnormalities, there are several treatments that might help relieve symptoms. Treatments differ from person to person and are dependent on the type of mitochondrial dysfunction that has been detected. The Mito Cocktail consists of a combination of vitamin supplements such as acetyl-L-carnitine (ALCAR), coenzyme Q10 (CoQ10), and alpha-lipoic acid (ALA), and creatine monohydrate, which is the most common form of treatment (CM). It is a scientifically based mix of vitamins, cofactors, and nutrients that are known to replace deficits that develop when the mitochondrial energy production system fails and to improve the residual function of the mitochondrial energy production system.

Additionally, One of the most useful medicines is exercise, which has been clinically verified (as long as the patient can tolerate it). On a biological level, exercise boosts energy production, which enhances mitochondrial function and increases the number of healthy mitochondria in the cells. According to studies, exercise improves exercise tolerance and metabolism by allowing the body to use oxygen more efficiently. Thus, from the above statements, the market segment is expected to hold the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global mitochondrial myopathies treatment market

In 2021, North America accounted for the highest revenue share. With the increasing prevalence of Mitochondrial Myopathies, rising demand for mitochondrial-based therapeutics, advancements in diagnostic facilities, and rising number of clinical trials to develop effective drugs for the disease along with the rise in several FDA approvals for novel drugs and therapies in the region are some of the factors the market is expected to boost in the forecast period. For instance, Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) are one of the most common mitochondrial diseases, with an estimated incidence of 1 in 4000, and mitochondria are carried out in the tails of sperm cells and hence discharged outside the zygote during fertilization, only women may pass the disease on to their children.

Moreover, The North American Mitochondrial Disease Consortium (NAMDC), which is part of the Rare Disease Clinical Research Network (RDCRN), collects information from mitochondrial disease patients in a clinical patient registry, which aids researchers in finding and recruiting participants for future studies. Additionally, The US Food and Drug Administration granted orphan therapeutic status to Reneo Pharmaceutical's main drug candidate REN001, to treat primary mitochondrial myopathy in June 2020. Thus, from the above statements, the North American region is expected to hold the largest market share in the forecast period.

Competitive Landscape

Major key players in the mitochondrial myopathies treatment market are Pfanstiehl, Inc., Ajinomoto Co., Inc., BOTAY BIO-CHEM CO., LIMITED, Xi'an ZB Biotech Co., Ltd., Kaneka Corporation, Lonza, AdvaCare Pharma and NutraBio Labs, Inc.

Lonza Group:

Overview:

Lonza Group is a Swiss multinational manufacturing company for the pharmaceutical, biotechnology, and nutrition sectors, headquartered in Basel, with major facilities in Europe, North America, and South Asia. The company provides product development services to the pharmaceutical and biologics industries, including custom manufacturing of biopharmaceuticals and detection systems and services for the bioscience sector.

Product Portfolio:

Carnipure: Carnipure L-Carnitine is the nutrient needed to help support conversion of fat into metabolic energy. It provides benefits ranging from increasing blood flow, reducing markers of metabolic stress, decreasing muscle soreness and improving recovery time.

Why Purchase the Report?

• Visualize the composition of the mitochondrial myopathies treatment market segmentation by type, test type, drug type, treatment type, distribution channel and region highlighting the key commercial assets and players.

• Identify commercial opportunities in mitochondrial myopathies treatment market by analyzing trends and co-development deals.

• Excel data sheet with thousands of data points of mitochondrial myopathies treatment market- level 4/5 segmentation.

• PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

• Product mapping in excel for the key product of all major market players

The global mitochondrial myopathies treatment market report would provide an access to an approx. 45+ market data table, 40+ figures and 200 pages.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

• 3.1. Market Snippet by Type
• 3.2. Market Snippet by Test Type
• 3.3. Market Snippet by Drug Type
• 3.4. Market Snippet by Treatment Type
• 3.5. Market Snippet by Distribution Channel
• 3.6. Market Snippet by Region

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Innovative therapies in the clinical trials for the treatment of Mitochondrial Myopathies are expected to drive market growth.
  • 4.1.2. Restraints:
    • 4.1.2.1. Higher R&D costs is expected to hamper the market growth.
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Supply Chain Analysis
• 5.2. Pricing Analysis
• 5.3. Unmet Needs

6. COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 7.1.2. Market Attractiveness Index, By Type Segment
• 7.2. Kearns-Sayre Syndrome*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 7.3. Mitochondrial DNA depletion syndrome (MDS)
• 7.4. Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS)
• 7.5. Maternally inherited deafness and diabetes (MIDD)
• 7.6. Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)
• 7.7. Myoclonus epilepsy with ragged red fibers (MERRF)
• 7.8. Neuropathy, ataxia, and retinitis pigmentosa (NARP)
• 7.9. Pearson syndrome
• 7.10. Others

8. By Test Type

• 8.1. Introduction
  • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
  • 8.1.2. Market Attractiveness Index, By Test Type Segment
• 8.2. Genetic Test*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 8.3. Muscle biopsy
• 8.4. Blood enzyme test
• 8.5. Other tests

9. By Drug Type

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
  • 9.1.2. Market Attractiveness Index, By Drug Type Segment
• 9.2. CoQ10*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 9.3. L-carnitine
• 9.4. Creatine
• 9.5. Others

10. By Treatment Type

• 10.1. Introduction
  • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
  • 10.1.2. Market Attractiveness Index, By Treatment Type Segment
• 10.2. Vitamins*
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 10.3. Anti-oxidants
• 10.4. Supportive and Targeted Therapy
• 10.5. Others

11. By Distribution Channel

• 11.1. Introduction
  • 11.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.1.2. Market Attractiveness Index, By Distribution Channel Segment
• 11.2. Hospital Pharmacy*
  • 11.2.1. Introduction
  • 11.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 11.3. Retail Pharmacy
• 11.4. Online Pharmacy
• 11.5. Others

12. By Region

• 12.1. Introduction
  • 12.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 12.1.2. Market Attractiveness Index, By Region
• 12.2. North America
  • 12.2.1. Introduction
  • 12.2.2. Key Region-Specific Dynamics
  • 12.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 12.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
  • 12.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
  • 12.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
  • 12.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 12.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 12.2.8.1. U.S.
    • 12.2.8.2. Canada
    • 12.2.8.3. Mexico
• 12.3. Europe
  • 12.3.1. Introduction
  • 12.3.2. Key Region-Specific Dynamics
  • 12.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 12.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
  • 12.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
  • 12.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
  • 12.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 12.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 12.3.8.1. Germany
    • 12.3.8.2. U.K.
    • 12.3.8.3. France
    • 12.3.8.4. Italy
    • 12.3.8.5. Spain
    • 12.3.8.6. Rest of Europe
• 12.4. South America
  • 12.4.1. Introduction
  • 12.4.2. Key Region-Specific Dynamics
  • 12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
  • 12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
  • 12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
  • 12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 12.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 12.4.8.1. Brazil
    • 12.4.8.2. Argentina
    • 12.4.8.3. Rest of South America
• 12.5. Asia Pacific
  • 12.5.1. Introduction
  • 12.5.2. Key Region-Specific Dynamics
  • 12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
  • 12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
  • 12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
  • 12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 12.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 12.5.8.1. China
    • 12.5.8.2. India
    • 12.5.8.3. Japan
    • 12.5.8.4. Australia
    • 12.5.8.5. Rest of Asia Pacific
• 12.6. Middle East and Africa
  • 12.6.1. Introduction
  • 12.6.2. Key Region-Specific Dynamics
  • 12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
  • 12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
  • 12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
  • 12.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

13. Competitive Landscape

• 13.1. Key Developments and Strategies
• 13.2. Company Share Analysis
• 13.3. Product Benchmarking
• 13.4. List of Key Companies to Watch

14. Company Profiles

• 14.1. Pfanstiehl, Inc.*
  • 14.1.1. Company Overview
  • 14.1.2. Product Portfolio and Description
  • 14.1.3. Key Highlights
  • 14.1.4. Financial Overview
• 14.2. Ajinomoto Co., Inc.
• 14.3. BOTAY BIO-CHEM CO., LIMITED
• 14.4. Xi'an ZB Biotech Co., Ltd.
• 14.5. Kaneka Corporation
• 14.6. Lonza
• 14.7. AdvaCare Pharma
• 14.8. NutraBio Labs, Inc.

LIST NOT EXHAUSTIVE

15. Global Mitochondrial Myopathies Treatment Market - DataM

• 15.1. Appendix
• 15.2. About Us and Applications
• 15.3. Contact Us